Ivabradina Normon

Ivabradine Hydrochloride, the active ingredient in Ivabradina Normon, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used to treat chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate adult patients who require heart‑rate control.

GNH USA supplies Ivabradina Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks across Europe, Asia and the Americas, and adherence to stringent quality‑assurance standards.

Ivabradina Normon (ivabradine) is employed in cardiovascular disease states where selective heart‑rate reduction is beneficial.

- Chronic stable angina pectoris: lowers heart rate to improve exercise capacity and reduce anginal episodes. - Heart failure with reduced ejection fraction (NYHA class II–III): decreases heart rate, helping to lower hospitalization risk and improve functional status. - Patients unable to tolerate beta‑blockers: provides heart‑rate control without beta‑adrenergic blockade.

Ivabradina Normon may be associated with several adverse reactions, which are categorised by frequency.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: symptomatic slow heart rate. - Headache. - Dizziness. - Nausea.

Serious or Rare Side Effects: - Atrial fibrillation. - Severe bradyarrhythmias. - Hypotension. - Allergic reactions (rash, angioedema).

When prescribing Ivabradina Normon, clinicians should consider several safety measures.

- Dose adjustment in renal impairment: reduce dose in severe renal dysfunction. - Avoid in patients with sick sinus syndrome: contraindicated. - Monitor heart rate: ensure resting HR remains above 50 bpm. - Caution with concomitant CYP3A4 inhibitors: may increase plasma levels. - Pregnancy and lactation: use only if clearly needed; limited data. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Ivabradina Normon can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause excessive bradycardia. - Concomitant use with other heart‑rate lowering agents (beta‑blockers, diltiazem, verapamil) at high doses: risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may increase exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Digoxin: monitor for additive effects on heart rate.